Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Novo Nordisk's semaglutide spurs major weight loss in phase 2 obesity study
Novo Nordisk's semaglutide spurs major weight loss in phase 2 obesity study
Novo Nordisk's semaglutide spurs major weight loss in phase 2 obesity study
Submitted by
admin
on March 19, 2018 - 11:40pm
Source:
Fierce Pharma
News Tags:
Novo Nordisk
obesity
semaglutide
Headline:
Novo Nordisk's semaglutide spurs major weight loss in phase 2 obesity study
Do Not Allow Advertisers to Use My Personal information
